« Return to News | R&D Trends

Broad Institute joins Illumina Genome Network

Thursday, February 16, 2012 06:22 AM

The Broad Institute has joined the Illumina Genome Network (IGN) to offer its proprietary sample preparation processes for whole human genome sequencing.

Broad’s approach enables high-quality sequencing of challenging low input DNA (

There are millions of biological samples within the global research community, most of them largely inaccessible by standard sample prep approaches because they are embedded in paraffin blocks or of very low genomic representation. The new offering through IGN and Broad allows researchers to interrogate these valuable samples that had previously been unable to be sequenced, with the objective to accelerate discovery in critical fields such as oncology.

“Partnering with Illumina allows us to extend our mission by providing researchers worldwide with our capability of processing low input and FFPE samples that are essential to their research,” said Robert Nicol, Ph.D., director of operations and technology development in the genome sequencing platform at the Broad Institute.

Suitability of projects for these specialized services will be evaluated jointly by Broad and Illumina. Interested researchers should contact Illumina directly.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.